Calypte Biomedical to Present at the Wall Street Analyst Forum 47Th Annual Institutional Investor Conference.Business Editors ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 5, 2003 Calypte Biomedical Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CALY), the developer and marketer of the only two FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, today announced that it will be presenting at the Wall Street Analyst Forum 47th Institutional Investor Conference at The Roosevelt Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , New York on Monday, February 10, 2003 at 9:00 a.m. ET. Presenting for Calypte will be Tony Cataldo, chairman and Nancy Katz, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . The webcast presentation will also be broadcast over the Internet. To listen to the presentation, please go to the investor's section of Calypte's web site at www.calypte.com and register for the webcast presentation. An archived replay will be available after the conclusion of the presentation for 30 days. About Calypte Biomedical: Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. Type 1 (HIV-1), sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion